BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
New Cheetos and Doritos will be free of artificial dyes - 2Paratroopers kill terrorist who threw rocks at Israeli citizens, soldiers near Ofra in West Bank
- 3Should you get an RSV vaccine this fall? What to know and where to get a shot
- 4Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- 5Top 10 Moving Style Architects of the Year
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- Becoming Familiar with an Unknown dialect: My Language Learning Excursion
- Which Espresso Do You Like Best? Vote
- Make your choice for a definitive Christmas getaway destination!
- The Oscars are moving from ABC to YouTube starting in 2029
- The 15 Most Rousing TED Chats on Self-awareness
- Astrophotographer captures spectacular photo of Antennae Galaxies dueling in deep space
- What to know about King Charles III's cancer treatment and his message to the public
- Monetary Versatility: Get ready for Life's Unforeseen Difficulties
